{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:06:43Z","timestamp":1784149603320,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijid.2026.108473","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T22:54:25Z","timestamp":1770591265000},"page":"108473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: A retrospective analysis"],"prefix":"10.1016","volume":"165","author":[{"given":"Norbert","family":"Ndjeka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubeshan","family":"Perumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Romanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hlengani","family":"Mathema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lateef Babatunde","family":"Amusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon R.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conradie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik Simon","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Oelofse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8874-6661","authenticated-orcid":false,"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108473_bib0001","series-title":"2025 global tuberculosis report","year":"2025"},{"key":"10.1016\/j.ijid.2026.108473_bib0002","series-title":"Global update 2025","year":"2025"},{"key":"10.1016\/j.ijid.2026.108473_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2021.05.010","article-title":"Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: a systematic review","volume":"83","author":"Dillard","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2026.108473_bib0004","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-019-1155-4","article-title":"The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa","volume":"17","author":"Sineke","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ijid.2026.108473_bib0005","article-title":"Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.ijid.2026.108473_bib0006","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108473_bib0007","series-title":"Introduction of new drugs and drugs regimens for management of drug-resistant tuberculosis in South Africa. A policy framework version 1.1. 2015","year":"2015"},{"key":"10.1016\/j.ijid.2026.108473_bib0008","series-title":"Interim clinical guidance for implementation of injectable-free regimens for rifampicin-resistant tuberculosis in in adults, adolescents and children","year":"2018"},{"key":"10.1016\/j.ijid.2026.108473_bib0009","article-title":"Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey","volume":"18","author":"Ismail","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108473_bib0010","series-title":"Management of rifampicin-resistant tuberculosis: a clinical reference guide","year":"2019"},{"key":"10.1016\/j.ijid.2026.108473_bib0011","volume":"WHO\/UCN\/TB\/2022.2","year":"2022"},{"key":"10.1016\/j.ijid.2026.108473_bib0012","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment, 2022 update","year":"2022"},{"key":"10.1016\/j.ijid.2026.108473_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108473_bib0014","unstructured":"Conradie F., Phillips P., Badat T., Poswa A., Rajaram S., Nosipho N., et al. High rate of successful outcomes treating RR-TB with a delamanid-bedaquiline regimen in BEAT tuberculosis: an interim analysis. In: World Conference on Lung Health 2022 of The International Union Against Tuberculosis and Lung Disease; 2022; Virtual event. The Union; 2022."},{"key":"10.1016\/j.ijid.2026.108473_bib0015","article-title":"Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan","volume":"36","author":"Myrzaliev","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.ijid.2026.108473_bib0016","article-title":"The use of BPaL containing regimen in the MDR\/PreXDR TB treatments in Thailand","volume":"34","author":"Sangsayunh","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.ijid.2026.108473_bib0017","series-title":"WHO Operational Handbook on Tuberculosis Module 4: Treatment \u2013 Drug-Resistant Tuberculosis Treatment","year":"2022"},{"key":"10.1016\/j.ijid.2026.108473_bib0018","series-title":"Clinical management of rifampicin-resistant tuberculosis","year":"2023"},{"key":"10.1016\/j.ijid.2026.108473_bib0019","series-title":"Definitions and reporting framework for tuberculosis \u2013 2013 revision (updated December 2014 and January 2020)","year":"2014"},{"key":"10.1016\/j.ijid.2026.108473_bib0020","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017"},{"key":"10.1016\/j.ijid.2026.108473_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad312","article-title":"Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant tuberculosis disease","volume":"77","author":"Haley","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108473_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310773","article-title":"Introducing BPaL: experiences from countries supported under the LIFT-TB project","volume":"19","author":"Wares","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.108473_bib0023","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5588\/ijtldopen.24.0369","article-title":"Experience of piloting BPaLM\/BPaL for DR-TB care at selected sites in Pakistan","volume":"1","author":"Khan","year":"2024","journal-title":"IJTLD Open"},{"key":"10.1016\/j.ijid.2026.108473_bib0024","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/cid\/ciae145","article-title":"Treatment of multidrug-resistant or rifampicin-resistant tuberculosis with an all-oral 9-month regimen containing linezolid or Ethionamide in South Africa: a retrospective cohort study","volume":"78","author":"Morgan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108473_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111575","article-title":"Derivation and clinical utility of safety targets for linezolid-related adverse events in drug-resistant tuberculosis treatment","volume":"16","author":"Keutzer","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijid.2026.108473_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky096","article-title":"Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation","volume":"73","author":"Millard","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108473_bib0027","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijid.2026.108473_bib0028","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An all-oral 6-month regimen for multidrug-resistant tuberculosis A multicenter, randomized controlled clinical trial (The NExT study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2026.108473_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2019.04.028","article-title":"Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen","volume":"85","author":"Olayanju","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108473_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad653","article-title":"The safety and tolerability of Linezolid in novel short-course regimens containing Bedaquiline, Pretomanid, and Linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108473_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108473_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0296448","article-title":"Global adoption of 6-month drug-resistant TB regimens: projected uptake by 2026","volume":"19","author":"Gupta","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.108473_bib0033","doi-asserted-by":"crossref","DOI":"10.7196\/SAMJ.2023.v113i11.497","article-title":"Treating drug-resistant tuberculosis in an era of shorter regimens: insights from rural South Africa","volume":"113","author":"Lotz","year":"2023","journal-title":"S Afr Med J"},{"key":"10.1016\/j.ijid.2026.108473_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf112","article-title":"Treatment outcomes with an oral short course regimen for rifampicin-resistant tuberculosis in a high HIV prevalence, programmatic setting in South Africa","volume":"81","author":"Stadler","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108473_bib0035","article-title":"Adverse event reporting practices in drug-resistant tuberculosis facilities across South Africa","volume":"38","author":"Gaida","year":"2023","journal-title":"S Afr J Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:11:44Z","timestamp":1784146304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"alternative-id":["S1201971226001086"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108473","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: A retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108473"}}